ACLX
Arcellx, Inc.
54.98
USD
This page is just a preview of the data found in TrendSpider’s full version
Arcellx, Inc. stock is up 23.19% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 26 Oct 17:43 | 15 Dec, 2023 | 35.00 | 5 | ||
| 14 Nov 15:17 | 17 May, 2024 | 35.00 | 15 | ||
| 17 Nov 16:57 | 17 May, 2024 | 35.00 | 28 |
Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.
